Renal Cell Carcinoma (Event Driven)

Transcription

1 Brochure More information from Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that Pfizer s axitinib which has been filed for regulatory approval in 2011 in Europe and the United States Aveo Pharmaceuticals/Astellas Pharma/Kyowa Hakko Kirin s tivozanib, and Novartis s dovitinib will launch in this indication during our forecast period and will further bolster the market. However, a large unmet need to improve the prognosis of RCC patients remains. Contents: Executive Summary What are the key parameters of the RCC market? What factors are driving the market for RCC therapies? What factors are constraining the market for RCC therapies? What are the drug development activities of note in RCC? What do the experts say? What key challenges and opportunities remain? 1. Etiology and Pathophysiology Disease Pathophysiology Risk Factors Genetic and Hereditary Factors Other Risk Factors Cellular Classification Clear-Cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Collecting-Duct Carcinoma Unclassified Renal Cell Carcinoma Molecular Markers Staging Symptoms Prognosis Spread of Renal Cell Carcinoma Recurrence Pathways and Drug Targets 2. Epidemiology and Patient Populations Disease Definition Methods Newly Diagnosed Incident Cases Recurrent Incident Cases Staging Diagnosed and Drug-Treated Populations Percentage Diagnosed Percentage Drug-Treated Stage IV, First-Line Drug-Treatable Population Stage IV, Second-Line Drug-Treatable Population Stage IV, Third-Line Drug-Treatable Population 3. Current Therapies and Medical Practice Renal Cell Carcinoma Diagnosis Treatment Guidelines Clinical Trial End Points

2 Drug Treatment Commonly Prescribed Drugs Regimen Dosing Clinical Analysis of Therapies Used as First-Line Treatment for Advanced Renal Cell Carcinoma Clinical Analysis of Therapies Used as Second-Line Treatment for Advanced Renal Cell Carcinoma Clinical Analysis of Therapies Used as Third-Line Treatment for Advanced Renal Cell Carcinoma Clinical Development Treatment Algorithm Country-Specific Medical Practice Reimbursement 4. Unmet Needs Improved Survival for Advanced RCC Patients Adjuvant Therapy for Patients with Localized Disease at Intermediate and High Risk of Relapse Optimized Treatment by Line of Therapy Biomarkers to Aid in Diagnosis and Treatment Agents for Non-Clear-Cell RCC Improved Quality of Life with Advanced RCC Combination Use of RCC Agents 5. Emerging Therapies Future Positioning of Key Competitors Drug Development and Regulatory Hurdles Angiogenesis Inhibitors Mechanism of Action Axitinib Tivozanib Dovitinib Ramucirumab Foretinib Immunotherapies Mechanism of Action Girentuximab Naptumomab Estafenatox IMA-901 AGS-003 Vitespen Renal Cell Carcinoma 6. Market Outlook Drug-Class-Specific Trends Angiogenesis Inhibitors Mammalian Target of Rapamycin (mtor) Inhibitors Cytokines Segment-Specific Trends Stage IV First-Line Setting Stage IV Second-Line Setting Stage IV Third-Line Setting Alternative Market Scenarios Appendix A. Bibliography Renal Cell Carcinoma Appendix B. Market Forecast Methodology Bottom-Up Market Forecasting

3 Patient Populations Drug-Specific Assumptions Drug-Specific Assumptions General Sources of Data Pricing, Dosing, Days of Therapy, and Compliance Assumptions General Statements About Pricing Dosing, Cycles and Compliance Generic Erosion Emerging Therapy Prices Appendix C. Experts Interviewed Renal Cell Carcinoma Tables and Figures Renal Cell Carcinoma Table 1-1. Lifestyle Factors Linked to the Development of Renal Cell Carcinoma Table 1-2. Select Genes Reportedly Involved in Renal Cell Carcinoma Table 1-3. Definitions of the TNM Staging System for Renal Cell Carcinoma Table 1-4. TNM Staging System for Renal Cell Carcinoma Table 1-5. UCLA Integrated Staging System Renal Cell Carcinoma Risk Groups Table 1-6. The Memorial Sloan-Kettering Cancer Center Risk Assessment System for Stage IV Renal Cell Carcinoma Patients Table 2-1. Number of Diagnosed Incident Cases of Renal Cell Carcinoma in the Major Pharmaceutical Markets by Stage at Diagnosis, Table 2-2. Drug-Treatable Renal Cell Carcinoma Populations, by Stage, Table 2-3. Key Sources for Renal Cell Carcinoma Epidemiology and Patient Flow Model Table 3-1. Treatment Providers and Diagnostic Patterns in the Major Markets for Renal Cell Carcinoma Table 3-2. Renal Cell Carcinoma Treatment Guidelines, by Market Table 3-3. Key End Points Used in Clinical Trials for Renal Cell Carcinoma Table 3-4. Current Therapies Used for Renal Cell Carcinoma Mechanism of Action Table 3-5. Key Therapeutic Approaches to Treatment of Stage IV Renal Cell Carcinoma Table 3-6. Brand and Manufacturer of Current Therapies to Treat Renal Cell Carcinoma Table 3-7. Current Drug and Regimen Dosing for Renal Cell Carcinoma Table 3-8. Expert Insight: Sunitinib vs. Pazopanib Table 3-9. Efficacy Achievements for Renal Cell Carcinoma in First-Line Therapy Table Most Frequent Toxicities Encountered During First-Line Treatment of Renal Cell Carcinoma Table Efficacy Achievements in Second- and Subsequent-Line Treatment of Renal Cell Carcinoma Table Most Frequent Toxicities Encountered During Second- and Subsequent-Line Treatment of Renal Cell Carcinoma Table Select Trials Investigating Therapies in the Treatment of Renal Cell Carcinoma Table Expert Insight: Therapies Used to Treat Renal Cell Carcinoma Table Reimbursement Environment for Renal Cell Carcinoma, by Market Table 5-1. Emerging Therapies in Development for Renal Cell Carcinoma Table 5-2. Estimated Launch Dates of Key Emerging Therapies for the Treatment of Renal Cell Carcinoma Table 5-3. Main Targets of Current and Emerging Renal Cell Carcinoma Angiogenesis Inhibitors Table 6-1. Sales of Drugs to Treat Renal Cell Carcinoma (All Populations) in the Major Renal Cell Carcinoma Pharmaceutical Markets, Table 6-2. Timeline of Key Market Events for Renal Cell Carcinoma Table 6-3. Alternative Scenarios for the Renal Cell Carcinoma Market Through 2020 Table B-1. Sources for Drug Prices Table B-2. Current Drug and Regimen Dosing for Renal Cell Carcinoma Figure 1-1. The Kidney Figure 1-2. The VHL Pathway Drug Targets for Renal Cell Carcinoma. Figure 1-3. Five-Year Survival Rate as Determined by AJCC Disease Stage for Renal Cell Carcinoma Figure 2-1. Crude Incidence of Renal Cell Carcinoma in the Major Pharmaceutical Markets, by Gender, 2009 Figure 3-1. Treatment Algorithm for Renal Cell Carcinoma Figure 4-1. Unmet Needs: Attainment and Remaining Opportunity in Renal Cell Carcinoma Figure 6-1. Renal Cell Carcinoma Therapies, , Market Share Figure 6-2. Renal Cell Carcinoma Therapy Sales by Region, Figure 6-3. Renal Cell Carcinoma Therapy Sales, by Line, Figure 6-4. Timeline of Near-Term Events in Renal Cell Carcinoma Figure 6-5. Sales of Major Drugs in the Renal Cell Carcinoma First-Line Market, Figure 6-6. Sales of Major Drugs in the Renal Cell Carcinoma Second-Line Market,

4 Figure 6-7. Sales of Major Drugs in the Renal Cell Carcinoma Third-Line Market, Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct. Product Name: Web Address: Office Code: Renal Cell Carcinoma (Event Driven) SC Product Format Please select the product format and quantity you require: Electronic (PDF) - Single User: Quantity USD Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

6 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World